CORSA study finds spike-specific blunted immune responses in lymphoma patients after SARS-CoV-2 vaccine - Takeaways - MDSpire

CORSA study finds spike-specific blunted immune responses in lymphoma patients after SARS-CoV-2 vaccine

  • By

  • Lucia Mazzotti

  • Gerardo Musuraca

  • Fabio Affaticati

  • Esther Bartholomeus

  • Diana Campillo-Davo

  • Carole Faghel

  • Chiara Zingaretti

  • Flavia Foca

  • Claudio Cerchione

  • Valentina Ancarani

  • Patricia Borges de Souza

  • Fabio Nicolini

  • Anna De Lucia

  • Anna Gaimari

  • Oriana Nanni

  • Vittorio Sambri

  • Giovanni Martinelli

  • Francesco Malaspina

  • Pieter Meysman

  • Eva Lion

  • Massimiliano Mazza

  • May 20, 2026

  • 0 min

Share

  • 1

    The CORSA trial assessed immune responses to SARS-CoV-2 vaccines in 77 lymphoma patients undergoing active treatment compared to healthy controls.

  • 2

    Seroconversion rates were significantly lower in lymphoma patients, with only 8% and 21% achieving seroconversion after the first and second vaccine doses, respectively.

  • 3

    Despite poor antibody responses, 69% of seronegative lymphoma patients exhibited measurable T-cell activity, indicating some vaccine-induced protection.

  • 4

    Lymphoma patients showed significantly weaker Spike-specific T-cell clonal responses and reduced diversity compared to healthy controls.

  • 5

    The findings highlight the increased vulnerability of lymphoma patients to SARS-CoV-2, emphasizing the need for tailored vaccination strategies.

Original Source(s)

CORSA study finds spike-specific blunted immune responses in lymphoma patients after SARS-CoV-2 vaccine

  • by Lucia Mazzotti, Gerardo Musuraca, Fabio Affaticati, Esther Bartholomeus, Diana Campillo-Davo, Carole Faghel, Chiara Zingaretti, Flavia Foca, Claudio Cerchione, Valentina Ancarani, Patricia Borges de Souza, Fabio Nicolini, Anna De Lucia, Anna Gaimari, Oriana Nanni, Vittorio Sambri, Giovanni Martinelli, Francesco Malaspina, Pieter Meysman, Eva Lion, Massimiliano Mazza

  • May 20, 2026

Related Content

When Adnexal Lymphoma Mimics Retinal Disease

Molecular Pathology Insights into Hematologic Malignancies: An In-Depth Analysis of Genetic and Chromosomal Abnormalities and Their Clinical Implications

Blocking CD30 on CD19 CAR T cells augments their functional capacities against B-cell leukemia/lymphoma